Phospholipase C activator m-3M3FBS protects against morbidity and mortality associated with sepsis

Journal of Immunology

Volumn 189, Issue 4, 2012, Pages 2000-2005

  Kim, Sang Doo ^a,b   Kim, Hak Jung ^a,b   Shim, Jae Woong ^a   Lee, Ha Young ^a,b   Lee, Sung Kyun ^a,b   Kwon, Soonil ^a,b   Jung, Young Su ^a,b   Baek, Suk Hwan ^c   Park, Joon Seong ^d   Zabel, Brian A ^e   Bae, Yoe Sik ^a,b  

^a Sungkyunkwan University   (South Korea)

^b Dong A University   (South Korea)

^c Yeungnam University College of Medicine   (South Korea)

^d Ajou University School of Medicine   (South Korea)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; CEPHALOSPORIN; ENZYME ACTIVATOR; GAMMA INTERFERON; GENTAMICIN; HYDROGEN PEROXIDE; INTERLEUKIN 12; INTERLEUKIN 1BETA; M 3M3FBS; PHOSPHOLIPASE C; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATTENUATION; BACTERIAL CLEARANCE; BACTERICIDAL ACTIVITY; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ESCHERICHIA COLI; IMMUNOCOMPETENT CELL; IN VIVO STUDY; INFECTION PREVENTION; INFLAMMATION; INTERFERON PRODUCTION; LETHALITY; MALE; MORBIDITY; MORTALITY; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE;

ANIMALS; APOPTOSIS; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MICE; MICE, INBRED ICR; NEUTROPHILS; SEPSIS; SULFONAMIDES; TYPE C PHOSPHOLIPASES;

EID: 84864801367     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200635     Document Type: Article

References (31)

1. Cohen, J. 2002. The immunopathogenesis of sepsis. Nature 420: 885-891. (Pubitemid 36019643)
2. Angus, D. C., W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29: 1303-1310. (Pubitemid 32641789)
3. Aneja, R., and M. P. Fink. 2007. Promising therapeutic agents for sepsis. Trends Microbiol. 15: 31-37. (Pubitemid 46038730)
4. Döcke, W. D., F. Randow, U. Syrbe, D. Krausch, K. Asadullah, P. Reinke, H. D. Volk, and W. Kox. 1997. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat. Med. 3: 678-681. (Pubitemid 27264980)
5. Czermak, B. J., V. Sarma, C. L. Pierson, R. L. Warner, M. Huber-Lang, N. M. Bless, H. Schmal, H. P. Friedl, and P. A. Ward. 1999. Protective effects of C5a blockade in sepsis. Nat. Med. 5: 788-792. (Pubitemid 29318613)
6. Calandra, T., B. Echtenacher, D. L. Roy, J. Pugin, C. N. Metz, L. Hültner, D. Heumann, D. Männel, R. Bucala, and M. P. Glauser. 2000. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat. Med. 6: 164-170. (Pubitemid 30082360)
7. Hotchkiss, R. S., K. W. Tinsley, P. E. Swanson, R. E. Schmieg, Jr., J. J. Hui, K. C. Chang, D. F. Osborne, B. D. Freeman, J. P. Cobb, T. G. Buchman, and I. E. Karl. 2001. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J. Immunol. 166: 6952-6963. (Pubitemid 32467243)
8. Wang, S. D., K. J. Huang, Y. S. Lin, and H. Y. Lei. 1994. Sepsis-induced apoptosis of the thymocytes in mice. J. Immunol. 152: 5014-5021.
9. Gogos, C. A., E. Drosou, H. P. Bassaris, and A. Skoutelis. 2000. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J. Infect. Dis. 181: 176-180. (Pubitemid 30049046)
10. Reinhart, K., and W. Karzai. 2001. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit. Care Med. 29(7, Suppl.): S121-S125. (Pubitemid 32681594)
11. Ulloa, L., and K. J. Tracey. 2005. The "cytokine profile": a code for sepsis. Trends Mol. Med. 11: 56-63.
12. Noh, D. Y., S. H. Shin, and S. G. Rhee. 1995. Phosphoinositide-specific phospholipase C and mitogenic signaling. Biochim. Biophys. Acta 1242: 99-113.
13. Jiang, H., Y. Kuang, Y. Wu, W. Xie, M. I. Simon, and D. Wu. 1997. Roles of phospholipase C β2 in chemoattractant-elicited responses. Proc. Natl. Acad. Sci. USA 94: 7971-7975.
14. Stokes, L., and A. Surprenant. 2007. Purinergic P2Y2 receptors induce increased MCP-1/CCL2 synthesis and release from rat alveolar and peritoneal macrophages. J. Immunol. 179: 6016-6023.
15. Graham, D. B., C. M. Robertson, J. Bautista, F. Mascarenhas, M. J. Diacovo, V. Montgrain, S. K. Lam, V. Cremasco, W. M. Dunne, R. Faccio, et al. 2007. Neutrophil-mediated oxidative burst and host defense are controlled by a Vav-PLCγ2 signaling axis in mice. J. Clin. Invest. 117: 3445-3452. (Pubitemid 350097000)
16. Bae, Y. S., T. G. Lee, J. C. Park, J. H. Hur, Y. Kim, K. Heo, J. Y. Kwak, P. G. Suh, and S. H. Ryu. 2003. Identification of a compound that directly stimulates phospholipase C activity. Mol. Pharmacol. 63: 1043-1050. (Pubitemid 36529922)
17. Segal, A. W. 2005. How neutrophils kill microbes. Annu. Rev. Immunol. 23: 197-223. (Pubitemid 40563169)
18. Yan, J. J., J. S. Jung, J. E. Lee, J. Lee, S. O. Huh, H. S. Kim, K. C. Jung, J. Y. Cho, J. S. Nam, H. W. Suh, et al. 2004. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat. Med. 10: 161-167. (Pubitemid 38524886)
19. Liu, D., B. X. Zeng, S. H. Zhang, and S. L. Yao. 2005. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces pulmonary inflammatory response in a rat model of endotoxemia. Inflamm. Res. 54: 464-470. (Pubitemid 41690375)
20. Bae, Y. S., H. J. Yi, H. Y. Lee, E. J. Jo, J. I. Kim, T. G. Lee, R. D. Ye, J. Y. Kwak, and S. H. Ryu. 2003. Differential activation of formyl peptide receptor-like 1 by peptide ligands. J. Immunol. 171: 6807-6813.
21. Wang, J., J. P. Silva, C. M. Gustafsson, P. Rustin, and N. G. Larsson. 2001. Increased in vivo apoptosis in cells lacking mitochondrial DNA gene expression. Proc. Natl. Acad. Sci. USA 98: 4038-4043. (Pubitemid 32249894)
22. 2+ homeostasis independently of phospholipase C activation. Br. J. Pharmacol. 143: 3-7.
23. Hampton, M. B., A. J. Kettle, and C. C. Winterbourn. 1998. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 92: 3007-3017. (Pubitemid 28492304)
24. Kox, W. J., R. C. Bone, D. Krausch, W. D. Döcke, S. N. Kox, H. Wauer, K. Egerer, S. Querner, K. Asadullah, R. von Baehr, and H. D. Volk. 1997. Interferon γ-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch. Intern. Med. 157: 389-393. (Pubitemid 27089964)
25. Moreno, S. E., J. C. Alves-Filho, T. M. Alfaya, J. S. da Silva, S. H. Ferreira, and F. Y. Liew. 2006. IL-12, but not IL-18, is critical to neutrophil activation and resistance to polymicrobial sepsis induced by cecal ligation and puncture. J. Immunol. 177: 3218-3224. (Pubitemid 44277840)
26. Nakano, N., C. Nishiyama, S. Kanada, Y. Niwa, N. Shimokawa, H. Ushio, M. Nishiyama, K. Okumura, and H. Ogawa. 2007. Involvement of mast cells in IL-12/23 p40 production is essential for survival from polymicrobial infections. Blood 109: 4846-4855. (Pubitemid 46827781)
27. Göebel, A., E. Kavanagh, A. Lyons, I. B. Saporoschetz, C. Soberg, J. A. Lederer, J. A. Mannick, and M. L. Rodrick. 2000. Injury induces deficient interleukin-12 production, but interleukin-12 therapy after injury restores resistance to infection. Ann. Surg. 231: 253-261. (Pubitemid 30078809)
28. Kim, S. D., Y. K. Kim, H. Y. Lee, Y. S. Kim, S. G. Jeon, S. H. Baek, D. K. Song, S. H. Ryu, and Y. S. Bae. 2010. The agonists of formyl peptide receptors prevent development of severe sepsis after microbial infection. J. Immunol. 185: 4302-4310.
29. Fisher, C. J., Jr., J. F. Dhainaut, S. M. Opal, J. P. Pribble, R. A. Balk, G. J. Slotman, T. J. Iberti, E. C. Rackow, M. J. Shapiro, R. L. Greenman, et al. 1994. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271: 1836-1843.
30. Opal, S. M., C. J. Fisher, Jr., J. F. Dhainaut, J. L. Vincent, R. Brase, S. F. Lowry, J. C. Sadoff, G. J. Slotman, H. Levy, R. A. Balk, et al. 1997. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit. Care Med. 25: 1115-1124. (Pubitemid 27310249)
31. Remick, D. G., D. E. Newcomb, G. L. Bolgos, and D. R. Call. 2000. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock 13: 110-116